Immortal Dragons, a longevity fund with an investment of $40 million, has made a strategic investment in Unlimited Bio, a biotechnology firm focused on developing combinatorial therapies aimed at addressing the complex nature of aging. This announcement was made on October 22, 2025, in Singapore.
The collaboration between these two entities highlights the growing interest in innovative approaches to combat aging, which is increasingly recognized as a multi-system challenge. By leveraging combinatorial therapies, Unlimited Bio aims to tackle the various biological pathways involved in the aging process.
Investments in biotechnology and longevity research have surged in recent years as scientists and investors alike seek solutions to extend healthy lifespan and improve overall well-being. The partnership with Immortal Dragons underscores the potential for significant advancements in this field.
As research continues to evolve, the implications of these therapies could pave the way for groundbreaking treatments that may redefine aging and longevity.
